.Pharmacolibrary.Drugs.ATC.C.C10AX16 .Pharmacolibrary.Drugs.ATC.C.C10AX16| name: | Inclisiran |
| ATC code: | C10AX16 | route: | subcutaneous |
| n-compartments | 2 |
Inclisiran is a small interfering RNA (siRNA) drug that targets and degrades PCSK9 mRNA in the liver, leading to lower levels of LDL cholesterol. It is used in the treatment of hypercholesterolemia and is approved for use in adults with elevated LDL-C who are at high risk for cardiovascular events.
Pharmacokinetics in adult subjects with hypercholesterolemia or mixed dyslipidemia after a single subcutaneous dose.
Yamashita, S, et al., & Kajinami, K (2024). Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15. Journal of atherosclerosis and thrombosis 31(6) 876–903. DOI:10.5551/jat.64454 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38220186
Luo, Z, et al., & He, Y (2023). The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. Journal of clinical lipidology 17(3) 392–400. DOI:10.1016/j.jacl.2023.04.010 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37164838
Jeon, JY, et al., & Mitra, A (2022). Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics - a Minireview. Pharmaceutical research 39(8) 1749–1759. DOI:10.1007/s11095-022-03333-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35819583